Antimicrobial immunotherapies (Alphamer platform) against drug-resistant Gram-negative infections.
| Date | Round | Amount |
|---|---|---|
| Feb 2026 | Series A UK-based Centauri Therapeutics received £6 million from the AMR Action Fund, extending its Series A to £30 million, to take CTX-187 into Phase I trials. | $7.6M |
| Nov 2024 | Grant London immunotherapy startup Centauri Therapeutics won a 1M GBP grant from PACE to develop its Alphamer technology against Gram-negative bacteria. | $1.3M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.